Associated Papers
Single-nucleotide polymorphisms of donor CYP3A5 and recipient ABCB1 affect tacrolimus intrapatient variability in living donor liver transplantation: a retrospective cohort study.
Gongor SO et al.
Annals of Surgical Treatment and Research, 2025
Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation.
He S et al.
Cancer Chemotherapy and Pharmacology, 2023
Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients.
Contreras-Castillo S et al.
Frontiers in Pharmacology, 2021
Influence of POR*28 Polymorphisms on CYP3A5*3-Associated Variations in Tacrolimus Blood Levels at an Early Stage after Liver Transplantation.
Nakamura T et al.
International Journal of Molecular Sciences, 2020
Identification of genetic variants associated with tacrolimus metabolism in kidney transplant recipients by extreme phenotype sampling and next generation sequencing.
Dorr CR et al.
The Pharmacogenomics Journal, 2019
Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation.
Woillard JB et al.
Frontiers in Pharmacology, 2017
The POR rs1057868-rs2868177 GC-GT diplotype is associated with high tacrolimus concentrations in early post-renal transplant recipients.
Liu S et al.
Acta Pharmacologica Sinica, 2016
[Associations of SLCO1B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients].
Liu S et al.
Yao Xue Xue Bao = Acta Pharmaceutica Sinica, 2016
A Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant Recipients.
Jannot AS et al.
Therapeutic Drug Monitoring, 2016
Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin.
Wei KK et al.
Clinical Drug Investigation, 2015
Multigene predictors of tacrolimus exposure in kidney transplant recipients.
Pulk RA et al.
Pharmacogenomics, 2015
Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients.
Ragia G et al.
Molecular Diagnosis & Therapy, 2014
Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin.
Elens L et al.
Pharmacogenetics and Genomics, 2013
Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men.
Yang G et al.
Clinical Therapeutics, 2011
Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase.
Agrawal V et al.
Pharmacogenetics and Genomics, 2010
Altered heme catabolism by heme oxygenase-1 caused by mutations in human NADPH cytochrome P450 reductase.
Pandey AV et al.
Biochemical and Biophysical Research Communications, 2010
Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency.
Gomes LG et al.
The Journal of Clinical Endocrinology and Metabolism, 2009
[Association between dysplastic development of ventricular wall and primary cardiomyopathy: pathomorphological observations on 92 hearts from transplant recipients.].
Song LF et al.
Zhonghua Xin Xue Guan Bing Za Zhi, 2008
P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity.
Hart SN et al.
Expert Opinion on Drug Metabolism & Toxicology, 2008
Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism.
Hart SN et al.
Pharmacogenetics and Genomics, 2008